Victor A. Chow, MD
Patients with large B-cell lymphoma who experience disease progression following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy have poor long-term outcomes. Therefore, effective therapeutic strategies need to be identified for this patient population, explained Victor A. Chow, MD.
, Chow, who was the lead author of this retrospective study, highlighted the trial, its findings, and the next steps in understanding how to treat patients who progress after CAR T-cell therapy.
OncLive: Could you provide background to this study, which looked at disease progression after CD19-targeted CAR T-cell therapy?
: This study really came about [because] as lymphoma specialists, we see a lot of patients, unfortunately, with relapsed/refractory large B-cell lymphomas after CAR T-cell therapies. In the last year, [there] has been a huge change and dramatic shift in terms of treatment options for patients with not many very good options. We have been seeing a lot of good outcomes from CAR T-cell therapy, but unfortunately, there is still a good proportion of patients who still relapse disease following CD19-specific CAR T-cell therapy.
... to read the full story